166
- Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive
system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-
like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270–6.
doi:10.1016/j.jash.2012.04.004. - Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, et al. Renal
denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure.
Hypertension. 2007;49:373–9. doi:10.1161/01.HYP.0000253507.56499.bb. - Wallbach M, Halbach M, Reuter H, Passauer J, Lüders S, Böhning E, et al. Baroreflex activa-
tion therapy in patients with prior renal denervation. J Hypertens. 2016; doi:10.1097/
HJH.0000000000000949. - Iliescu R, Lohmeier TE. Lowering of blood pressure during chronic suppression of central
sympathetic outflow: insight from computer simulations. Clin Exp Pharmacol Physiol.
2010;37:e24–33. doi:10.1111/j.1440-1681.2009.05291.x. - Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal
denervation for treatment of patients with treatment-resistant hypertension: 36 month results
from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014; doi:10.1093/
eurheartj/ehu209. - Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled
trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.
doi:10.1056/NEJMoa1402670. - Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage:
clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514–23. doi:10.1038/
ajh.2011.245. - Vemulapalli S, Tyson CC, Svetkey LP. Apparent treatment-resistant hypertension and chronic
kidney disease: another cardiovascular-renal syndrome? Adv Chronic Kidney Dis. 2014;21:
489–99. doi:10.1053/j.ackd.2014.08.006. - Hildebrandt DA, Irwin ED, Cates AW, Lohmeier TE. Regulation of renin secretion and arterial
pressure during prolonged baroreflex activation: influence of salt intake. Hypertension.
2014;64:604–9. doi:10.1161/HYPERTENSIONAHA.114.03788. - Wolley MJ, Stowasser M. Resistant hypertension and chronic kidney disease: a dangerous
liaison. Curr Hypertens Rep. 2016;18:36. doi:10.1007/s11906-016-0641-x. - Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of
resistant hypertension and chronic kidney disease. Lancet. 2015;386:1588–98. doi:10.1016/
S0140-6736(15)00418-3. - Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv
Chronic Kidney Dis. 2015;22:116–22. doi:10.1053/j.ackd.2014.12.001. - Kaur M, Chandran DS, Jaryal AK, Bhowmik D, Agarwal SK, Deepak KK. Baroreflex dys-
function in chronic kidney disease. World J Nephrol. 2016;5:53–65. doi:10.5527/wjn.v5.i1.53. - Thomas P, Dasgupta I. The role of the kidney and the sympathetic nervous system in hyperten-
sion. Pediatr Nephrol. 2015;30:549–60. doi:10.1007/s00467-014-2789-4. - Garnier AS, Briet M. Arterial stiffness and chronic kidney disease. Pulse (Basel, Switzerland).
2016;3:229–41. doi:10.1159/000443616. - Sag AA, Covic A, London G, Vervloet M, Goldsmith D, Gorriz JL, et al. Clinical imaging of
vascular disease in chronic kidney disease. Int Urol Nephrol. 2016; doi:10.1007/
s11255-016-1240-0. - Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so
resistant to treatment? Kidney Int. 2006;69:967–73. doi:10.1038/sj.ki.5000177. - De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Prevalence and
prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol.
2013;61:2461–7. doi:10.1016/j.jacc.2012.12.061. - Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihyperten-
sive treatment resistance vs treatment failure. Can J Cardiol. 2016;32:603–6. doi:10.1016/j.
cjca.2015.06.033.
R. Iliescu and D.N. Şerban